News
KTRA
--
0.00%
--
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022
Upgrades
Benzinga · 5d ago
BRIEF-Kintara Therapeutics Posts Qtrly Net Loss Per Share $0.11
reuters.com · 05/13 12:17
Kintara Therapeutics GAAP EPS of -$0.11 beats by $0.03
Kintara Therapeutics press release (NASDAQ:KTRA): FQ3 GAAP EPS of -$0.11 beats by $0.03. Cash and cash equivalents of approximately $8.8M.
Seekingalpha · 05/13 12:17
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV
LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's Hotel & Casino in Las Vegas, NV.comThe Planet Micr...
ACCESSWIRE · 04/27 13:00
Kintara Therapeutics to Present at the Planet MicroCap Showcase 2022
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview a...
PR Newswire · 04/26 11:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 04/20 21:42
Stocks That Hit 52-Week Lows On Monday
    On Monday, 466 companies hit new 52-week lows.
Benzinga · 04/18 15:40
Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies today announced that it has closed its previously announced registered direct offering priced...
PR Newswire · 04/14 20:05
Kintara Therapeutics Closes $8.6 Million Registered Direct Offering
MT Newswires · 04/14 16:15
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers
Benzinga · 04/12 18:05
Here's Why Kintara Therapeutics (NASDAQ:KTRA) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 04/12 15:47
Kintara Therapeutics stock slumps on $8.6M securities offering
Kintara Therapeutics (NASDAQ:KTRA) shares dropped ~11% Tuesday morning after the biopharmaceutical company announced a $8.6M securities offering priced at-the-market under Nasdaq rules. The firm entered into definitive agreements with institutional investo...
Seekingalpha · 04/12 12:37
BRIEF-Kintara Reports $8.6 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
reuters.com · 04/12 12:34
Kintara Announces $8.6M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, April 12, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor
Benzinga · 04/12 12:33
Kintara Therapeutics Launches $8.6 Million Direct Offering; Shares Drop
MT Newswires · 04/12 10:38
Kintara Therapeutics Says 'For all three transporters VAL-083 was not a substrate for these active transport systems. This suggests that VAL-083 may be crossing the BBB by passive diffusion rather than facilitated active transport.'
VAL-083 shares structural and molecular similarities to glucose including low molecular weight and high water solubility. Glucose transporters, in particular GLUT1, are overexpressed by the BBB since the brain requires
Benzinga · 04/11 18:39
Kintara Therapeutics Presents Data At 2022 Annual Meeting
 Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that it
Benzinga · 04/11 18:31
Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual Meeting
Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that it has presented data at the 2022 American Association for Cancer Resea...
PR Newswire · 04/11 18:30
The Week Ahead In Biotech (April 10—April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Benzinga · 04/10 20:42
Webull provides a variety of real-time KTRA stock news. You can receive the latest news about Kintara Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KTRA
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The Company is carrying out various clinical trials on brain tumor and solid tumor.